Intestinal organoids: roadmap to the clinic

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Gastroenterology

Background:

• Intestinal organoid research shows therapeutic potential for induced pluripotent stem cell (iPSC)-derived organoids in treating bowel diseases.
• Preclinical studies highlight the promise of iPSC-derived organoids for healing and replacing damaged intestinal tissue.

Purpose of the Study:

• To outline critical areas and challenges in translating iPSC-derived organoid therapies from laboratory discovery to clinical application.
• To provide a roadmap for navigating regulatory requirements, including Investigational New Drug (IND) applications and first-in-human trials.

Main Methods:

• Review of current literature on intestinal organoid research and stem cell therapy translation.
• Identification of preclinical and clinical obstacles in the development of pluripotent stem cell-derived products.
• Emphasis on multidisciplinary collaboration between researchers, product developers, quality assurance, and regulatory affairs experts.

Main Results:

• Realizing the therapeutic potential of stem cell organoid-based therapies requires significant resources and effort to demonstrate safety and efficacy.
• Early identification of preclinical and clinical hurdles is essential for accelerating the bench-to-bedside translation of these novel products.
• Effective collaboration among diverse experts is necessary to overcome development and manufacturing challenges.

Conclusions:

• A strategic approach is needed to address safety, efficacy, and regulatory requirements for iPSC-derived organoid therapies.
• Investigators must consider regulatory steps early in the translational process to facilitate clinical application.
• This article serves as a guide for researchers navigating the development of iPSC-derived organoid cell therapies.